Pluri
Israeli regenerative medicine company developing cell therapy and tissue engineering products. Listed on NASDAQ, focused on cell therapy applications in wound healing and regenerative medicine.
Pluri (formerly Pluristem Therapeutics) is an Israeli regenerative medicine company that develops cell therapy and tissue engineering products derived from placental cells. Founded in 2001, Pluri pioneered isolation and expansion of placental-derived mesenchymal stem cells (MSCs) and has developed multiple clinical candidates.
Technology & Products
Pluri's core technology uses placental-derived cells (from amniotic membrane and chorionic villi) as starting material for allogeneic cell therapy products. These cells are expanded, characterized, and formulated for injection or topical application. Key products include PLX-PAD (for peripheral arterial disease and muscle injuries) and PLX-R18 (immunomodulation).
Clinical Pipeline
Pluri has multiple programs in clinical development: vascular regeneration (leg ischemia, diabetic foot ulcers), muscle repair (sports injuries, acute kidney injury), and immunomodulation (inflammation, graft-versus-host disease). Most programs are in Phase 2 trials; regulatory approval timelines remain uncertain.
Manufacturing & Scale
Pluri operates GMP (Good Manufacturing Practice) facilities in Israel and has partnered with contract manufacturers for large-scale production. Cell therapy manufacturing is capital-intensive and subject to strict regulatory oversight (FDA, EMA, Israeli Ministry of Health).
Capital Structure & Partnerships
Pluri raised venture funding (early rounds) and went public on NASDAQ. The company has partnerships with strategic investors (Kamedis, Roche venture arm) and research collaborations with academic centers (Hadassah, Tel Aviv University). Partnerships help offset R&D costs and validate clinical candidates.
Regulatory & Reimbursement Risk
Cell therapies face high regulatory scrutiny and slow approval timelines. Manufacturing complexity, immunogenicity, and long-term safety data requirements delay commercialization. Reimbursement is uncertain; payers scrutinize cell therapy pricing relative to conventional treatments.
Israeli Regenerative Medicine Ecosystem
Pluri is part of Israel's growing cell therapy and regenerative medicine sector. Other players include Gamida Cell (hematopoietic stem cells, acquired by Celgene/BMS), Hadassah Medical Center (research), and academic labs. This ecosystem attracts international partnerships and capital.